This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
The antiviral compound idoxuridine (IUDR) has been used in treatment of early smallpox by Yale University investigators.
In animal studies, the agent also has shown activity against two DNA dependent oncogenic viruses, Arnold D. Welch, MD, PhD, told the American Society of Pharmacology and Experimental Therapeutics.
The New Haven clinician noted these new clinical and experimental applications of idoxuridine as he accepted the third annual Torald Sollman Award for his work on "Enzyme reactions involved in the biosynthesis of metabolites." (See Miscellanea Medica p 40.)
The auditorium of Mexico City's massive Centro Medico Nacional, where the meetings were held, is an appropriate place. The walls are lined with portraits and statues of Mexico's medical heroes. Surrounding streets are named for outstanding clinicians.
Three patients were treated with intravenous idoxuridine recently at the Infectious Diseases Hospital, Madras, India. All had diagnosed smallpox and were "expected to die," noted Dr. Welch. The
New IUDR Uses Tested. JAMA. 1966;197(5):29-30. doi:10.1001/jama.1966.03110050015004